Diabetic kidney disease and its comorbid conditions, including atherosclerotic
cardiovascular disease, heart failure, diabetes, and obesity, are interconnected conditions
that compound the risk of kidney failure and cardiovascular mortality, and exponentiate
health care costs. Sodium glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like
peptide 1 receptor agonist (GLP-1 RA) are novel diabetes medications that prevent
cardiovascular events and kidney failure. Clinical trials exploring the cardiovascular and …